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The etiology of necrotizing enterocolitis (NEC) is multifactorial and an underlying
genetic predisposition to NEC is increasingly being recognized. A growing number
of studies identified single nucleotide polymorphisms (SNPs) of selected genes with
potential biological relevance in the development of NEC. However, few of these
genetic studies have been replicated in validation cohorts. We aimed to confirm in
a cohort of 358 preterm newborns (gestational age <30 weeks, 26 cases of NEC
≥ Bell stage II) the association with NEC of three candidate SNPs: the vascular
endothelium growth factor (VEGF ) C-2578A polymorphism (rs699947), the interleukin
(IL)-18 C-607A polymorphism (rs1946518), and the IL-4 receptor α-chain (IL-4Rα)
A-1902G polymorphism (rs1801275). We observed that allele and genotype frequencies
of the three SNPs did not significantly differ between the infants with and without NEC.
In contrast, the minor G-allele of the IL-4Rα A-1902G polymorphism was significantly
less frequent in the group of 51 infants with the combined outcome NEC or death before
34 weeks postmenstrual age than in the infants without the outcome (0.206 vs. 0.331,
P= 0.01). In addition, a significant negative association of the G-allele with the combined
outcome NEC or death was found using the dominant (adjusted odds ratio, aOR: 0.44,
95% CI 0.21–0.92), recessive (aOR 0.15, 95% CI 0.03–0.74), and additive (aOR 0.46,
95% CI 0.26–0.80) genetic models. In conclusion our study provides further evidence
that a genetic variant of the IL-4Rα gene may contribute to NEC.
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INTRODUCTION
Necrotizing enterocolitis (NEC) is the leading cause of morbidity
and mortality from gastrointestinal disease in very and extremely
preterm infants (1, 2). As extensively discussed in several
exhaustive reviews, the etiology of NEC is multifactorial and
largely related to immaturity of the gastrointestinal tract (1–
9). Besides low gestational age (GA), a complex interplay of
other factors, such as type of feeding, gut dysbiosis, the high
susceptibility of intestinal mucosal surface to inflammatory
processes, or intestinal hypoperfusion may contribute to the
pathogenesis of NEC (1–9). Nevertheless, NEC affects a minority
of (very) preterm infants and clinical risk factors provide
a limited explanation of the inter-individual variability in
NEC susceptibility (3, 10). In the last years, an underlying
genetic predisposition to NEC is increasingly being recognized
(3, 10, 11).
As recently reviewed by Cuna et al., the candidate gene
approach has been used in most studies on the genetics
of NEC (3). Using this approach, a growing number of
studies investigated single nucleotide polymorphisms (SNPs)
of selected genes based on a-priori hypothesis of relevance
to NEC. These studies particularly focused on mediators
involved in the regulation of immune/inflammatory responses,
such as toll like receptors, interleukins (ILs), tumor necrosis
factor, or nuclear factor-kappa beta, and in the control of
intestinal microcirculation, such as nitric oxide synthase, or
vascular endothelium growth factor (VEGF) (3). However, few
of these genetic studies have been replicated in validation
cohorts (3). In the present study we aimed to confirm the
association with NEC of three candidate SNPs: the VEGF C-
2578A polymorphism (rs699947) (12, 13), the IL-18 C-607A
polymorphism (rs1946518) (14), and the IL-4 receptor α-
chain (IL-4Rα) A-1902G polymorphism (rs1801275) (15). We
performed our investigation in a cohort of preterm infants from
four neonatal intensive care units located in three different
European countries (Spain, Italy, and the Netherlands) (16, 17).
MATERIALS AND METHODS
Patients
The present study was performed on DNA samples collected
during a previous study on carbamoyl phosphate synthetase
SNPs as risk factor for NEC (16). The protocol of the
above study was reviewed and approved by the institutional
review board (IRB) for each participating center (see names
below) and we obtained written informed consent from the
parents. The consent also allowed, after anonymization of
the DNA samples, the investigation of other SNPs potentially
involved in NEC development. The protocol is registered in
ClinicalTrials.gov Protocol Registration System (NCT00554866).
Additional approval was obtained for the present analysis. All
infants with a GA ≤30 weeks and birth weight (BW) ≤1,500 g
born between July 2007 and July 2012 and admitted to the level III
neonatal intensive care unit of the Maastricht University Medical
Center (the Netherlands, IRB number MEC-07-2-018), Hospital
Universitario Materno-Infantil de Canarias (Las Palmas de Gran
Canaria, Spain, IRB number CEIC- 276), Carlo Poma Hospital
(Mantova, Italy, inclusion until December 2011, IRB number
21366/2007), and Ospedale Maggiore Policlinico (Milan, Italy,
inclusion from January 2012, IRB number 220211b) were eligible
for participation in the study. As reported in a previous study,
buccal cell samples were obtained from 96 healthy term infants
(25 in Maastricht, 31 in Las Palmas de Gran Canaria and 40 in
Mantova) (18).
Definition of Clinical Characteristics and
Outcomes
Definitions were identical to those used in our previous study
(16) and are therefore literally reproduced here. Data on clinical
characteristics and outcomes were obtained from the medical
records. GA was determined by the last menstrual period and
early ultrasounds (before 20 weeks of gestation). Small for GA
was defined as BW for GA below the sex-specific 10th percentile.
Chorioamnionitis was defined as every clinical suspicion of
infection of the chorion, amnion, amniotic fluid, placenta, or a
combination as judged by the obstetrician. Prolonged rupture of
membranes was defined as rupture of membranes >24 h before
delivery. Prenatal exposure to a single course of antenatal steroids
was defined as two doses of betamethasone administered 24 h
apart and exposure to a partial course of antenatal steroids was
defined as administration of a single dose of betamethasone
<24 h prior to delivery.
NEC was defined as Bell stage II disease or greater. Cases of
NEC stage III were also separately analyzed. At the conclusion of
the study, all cases of NEC were reviewed in a blinded fashion
by a panel of 4 investigators of the study. Cases of spontaneous
intestinal perforation (i.e., without pathologic evidence of NEC)
were excluded from the NEC group. The control group for NEC
was formed by the infants without the condition who survived
until 34 weeks postmenstrual age (PMA). In another analysis,
we investigated the combined outcome NEC or death before 34
weeks PMA.
Arterial hypotension was defined as the need for volume
expansion or inotropic support. A diagnosis of sepsis required
signs of generalized infection, a positive blood culture, and
antibiotic therapy. Respiratory distress syndrome (RDS)
was defined as requirement for oxygen supplementation
or respiratory support due to tachypnea, grunting, nasal
flaring, retractions, or cyanosis. Bronchopulmonary dysplasia
(BPD) was defined as a supplemental oxygen requirement
at 36 weeks PMA to maintain oxygen saturation >90% (19).
Retinopathy of prematurity (ROP) was defined as stage II or
higher. Persistent ductus arteriosus (PDA) was defined as a
requirement for indomethacin or ibuprofen and/or surgical
ligation. Intraventricular hemorrhage (IVH) was classified by
using the 4-level grading system (20). Grade<2 IVHs were not
included in the analysis.
Samples and Genotyping
Buccal cell samples for DNA testing were obtained with a
sterile OmniSwab (Whatman) and collected in Eppendorf sterile
PCR tubes and stored at −80◦C until further analysis. The
samples obtained in Spain and Italy were transported on
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dry ice to Maastricht where all the analyses were performed.
DNA was extracted using standard methods and stored
at −20◦C until genotyping. Discrimination of the VEGF
rs699947, the IL-18 rs1946518, and the IL-4Rα rs1801275
alleles was performed with TaqMan R⃝ SNP genotyping assays
(Applied Biosystems, Foster City, CA, USA) ID C_8311602_10
(rs699947), C_2898460_10 (rs1946518), and C_2351160_20
(rs1801275), following the manufacturer’s instructions. The
TaqMan technique combines DNA amplification and genotype
detection in a single assay (21). Probe sequences are depicted
in Supplementary Table 1. Genotyping assays were performed
on an ABI PRISM 7900 Sequence Detection System for allelic
discrimination (Applied Biosystems).
Statistical Analysis
Methods for statistical analysis were identical to those used in our
previous study (16) and are therefore literally reproduced here.
Categorical variables were expressed as counts or percentages
and compared using the chi-square test. Continuous variables
were expressed as mean (SD) if they followed a normal
distribution and compared using unpaired, two-sided t-test. If
not normally distributed, continuous variables were expressed as
median values (interquartile range, IQR; 25th−75th percentile)
and compared using the using the Mann–Whitney U-test.
The Kolmogorov-Smirnov test was used to test for normal
distribution of continuous data.
Differences in allelic frequencies and genotype distributions
between the investigated populations, as well as Hardy–Weinberg
equilibrium (HWE) for genotype distribution were assessed
using a chi-square test. The Hardy–Weinberg law states that q2
+ 2pq + p2 = 1, where p and q are allele frequencies in a two-
allele system. Logistic regression analysis was used to compute
the odds ratios (ORs) and their 95% confidence intervals (CI) for
NEC and the combined outcome NEC or death before 34 weeks
of PMA based on genotype after accounting for the covariates
which were significantly different between the groups and are
known risk factors for developing NEC. Different genetic models
were used to analyze the effect of the risk allele including the
general allelic (multiplicative or codominant model), dominant,
recessive, and additive models. Assuming a genetic penetrance
parameter γ (γ >1), a multiplicative model indicates that the
risk of disease is increased γ-fold with each additional copy of
the risk allele; an additive model indicates that risk of disease
is increased γ-fold for the genotype with one copy of the risk
allele and 2 γ-fold for the genotype with two copies of the risk
allele; a common recessive model indicates that two copies of
the risk allele are required for a γ-fold increase in disease risk,
and a common dominant model indicates that either one or
two copies of the risk allele are required for a γ-fold increase in
disease risk (22). The major allele was considered as a reference
and the interactions were tested in the different models by
multivariable logistic regressionmodel. All the statistical analyses
were performed using IBM SPSS Statistics for Windows, Version
22.0. (IBM Corporation, Armonk, NY, USA) and conducted at
the P < 0.05 level of significance.
TABLE 1 | Baseline characteristics and neonatal complications in preterm infants
with and without NEC.
NEC-yes
(n = 26)
n data
missing
NEC-no
(n = 332)
n data
missing
P-value
Birth weight (g) 873 (SD 230) 0 1,040 (SD 259) 0 0.002
Gestational age (weeks) 26.8 (SD 1.9) 0 28.1 (SD 1.8) 0 0.000
Male sex 11 (42.3) 0 191 (57.5) 0 0.132
Prenatal steroids 18 (72) 1 278 (87.4) 14 0.097
Preecclampsia 2 (8.0) 1 52 (15.9) 5 0.293
Chorioamnionitis 0 (0.0) 0 35 (10.6) 3 0.080
PROM 6 (23.1) 0 95 (29.1) 5 0.516
Vaginal delivery 17 (65.4) 0 147 (44.5) 2 0.040
Apgar (1min) 5 [3–8] 1 6 [4–8] 3 0.184
Apgar (5min) 8 [6–9] 1 8 [7–9] 4 0.161
RDS 22 (84.6) 0 274 (82.8) 1 0.811
Mechanical vent. 23 (88.5) 0 202 (61.8) 5 0.006
BPD 15 (57.7) 0 92 (27.9) 2 0.001
Hypotension 19 (73.1) 0 118 (36.0) 4 0.000
Sepsis 17 (70.8) 2 174 (52.7) 2 0.086
IVH 14 (53.8) 0 93 (28.3) 3 0.006
PVL 3 (11.5) 0 13 (4.0) 4 0.073
PDA 15 (60.0) 1 140 (42.6) 3 0.090
ROP 8 (38.1) 5 51 (16.7) 27 0.014
Mortality 8 (30.8) 0 30 (9.0) 0 0.001
Death before 34 weeks 5 (19.2) 0 25 (7.5) 0 0.038
Results are expressed as mean (SD), median [interquartile range] or absolute numbers
of patients (percentage). NEC, necrotizing enterocolitis (≥stage II); PROM, prolonged
rupture of membranes; RDS, respiratory distress syndrome; BPD, bronchopulmonary
dysplasia; IVH, intraventricular hemorrhage (≥grade 2); PVL, periventricular leukomalacia;
PDA, patent ductus arteriosus; ROP, retinopathy of prematurity (≥stage II).
RESULTS
Patient Characteristics
A total number of 358 preterm infants (26 NEC cases) were
genotyped for the three SNPs, but genotype of VEGF C-2578A
SNP failed in 9 infants (1 from the NEC group) and genotype of
IL-18 C-607A SNP failed in 1 infant without NEC. Demographic
and clinical characteristics of the infants with and without NEC
are shown and compared in Table 1. Mean GA and mean BW of
infants with NEC were significantly lower than in infants without
NEC. In addition, infants with NEC showed a higher incidence
of vaginal delivery, mechanical ventilation, BPD, hypotension,
IVH, ROP, and mortality. We adjusted for GA, BW, mechanical
ventilation, hypotension, and death before 34 weeks PMA in the
subsequent logistic regression analysis.
The demographic and clinical characteristics of the infants
with and without the combined outcome NEC or death before
34 weeks PMA are shown and compared in Table 2. Mean GA,
mean BW and median Apgar score at 1 and 5min of infants with
NEC or death were significantly lower than in infants without
the combined outcome. In addition, infants with the combined
outcome NEC or death showed a higher incidence of vaginal
delivery, mechanical ventilation, hypotension, IVH, and PDA.
We adjusted for GA, BW, Apgar score after at 1 and 5min,
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TABLE 2 | Baseline characteristics and neonatal complications in preterm infants with and without the combined outcome NEC or death before 34 weeks of corrected
gestational age.
NEC/death-yes
(n = 51)
n data missing NEC/death-no
(n = 307)
n data missing P-value
Birth weight (g) 821 (SD 225) 0 1,063 (SD 250) 0 0.000
Gestational age (weeks) 26.3 (SD 1.9) 0 28.3 (SD 1.6) 0 0.000
Male sex 26 (42.7) 0 176 (57.3) 0 0.397
Prenatal steroids 31 (63.3) 2 259 (88.1) 13 0.060
Preecclampsia 3 (6.0) 1 51 (16.8) 4 0.049
Chorioamnionitis 6 (12.0) 1 29 (9.5) 2 0.584
PROM 15 (30.6) 2 86 (28.3) 3 0.738
Vaginal delivery 32 (62.7) 0 132 (56.7) 2 0.010
Apgar (1min) 5 [3–6] 1 6 [5-8] 6 0.000
Apgar (5min) 7 [6–8] 1 8 [7-9] 6 0.000
RDS 43 (84.3) 0 253 (82.7) 1 0.774
Mechanical vent. 48 (94.1) 0 177 (58.6) 5 0.000
BPD 18 (36.0) 1 89 (29.1) 1 0.323
Hypotension 42 (82.4) 0 95 (31.4) 4 0.000
Sepsis 30 (61.2) 2 161 (52.8) 2 0.271
IVH 28 (56.0) 1 79 (25.9) 2 0.000
PVL 4 (8.0) 1 12 (3.9) 3 0.201
PDA 32 (65.3) 2 123 (40.3) 2 0.001
ROP 8 (21.1) 13 51 (17.7) 19 0.615
Results are expressed as mean (SD), median [interquartile range] or absolute numbers of patients (percentage). NEC, necrotizing enterocolitis (≥stage II); PROM, prolonged rupture
of membranes; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage (≥grade 2); PVL, periventricular leukomalacia; PDA, patent
ductus arteriosus; ROP, retinopathy of prematurity (≥stage II).
mechanical ventilation, hypotension, and PDA in the subsequent
logistic regression analysis. We did not observe a significant
difference between the NEC and the control group in the rate of
exposure to antenatal steroids and therefore we did not control
for this exposure.
Analysis of Genotypes
Allele and genotype frequencies of the VEGF C-2578A, IL-
18 C-607A, and IL-4Rα A-1902G polymorphisms in the total
preterm population did not significantly differ from the allele and
genotype frequencies observed in the population of 96 healthy
term infants (Table 3) (18). The distribution of the genotypes of
the VEGF C-2578A- and the IL-4Rα A-1902G polymorphisms in
the preterm population and the IL-4Rα A-1902G polymorphism
in the term population did not fulfill Hardy-Weinberg criteria
(Table 3). The minor allele frequencies (MAFs) of the studied
polymorphisms in the NEC ≥ stage II, and NEC stage III groups
were not significantly different from the MAFs observed in the
infants without NEC (Table 4). The MAF of the IL-4Rα A-1902G
polymorphism was significantly lower (0.206 vs. 0.331, P = 0.01)
in the group of infants with the combined outcome NEC or death
before 34 weeks PMA than in the infants without the outcome
(Table 4). The MAFs of the VEGF C-2578A, and IL-18 C-607A
SNPS were not significantly different in the group of infants with
the combined outcome NEC or death before 34 weeks PMA than
in the infants without the outcome (Table 4). The distribution of
the genotypes of the VEGF C-2578A- and the IL-4Rα A-1902G
polymorphisms in the population of preterm infants without
NEC or without the combined outcome NEC/death did not fulfill
Hardy-Weinberg criteria (Table 4).
We further analyzed the effect of the VEGF C-2578A-,
IL-18 C-607A- and IL-4Rα A-1902G polymorphism on
the occurrence of NEC and NEC or death under different
genetic models. Logistic regression analysis could not
detect any significant association between the studied
polymorphisms and NEC ≥ stage II (Table 5), or NEC
stage III (Table 6) in any of the genetic models. In contrast,
the co-dominant, dominant, recessive, and additive model
showed a negative significant association of the G-allele
of the IL-4Rα A-1902G polymorphism with the combined
outcome NEC or death before 34 weeks of corrected gestational
age (Table 7).
DISCUSSION
Given that NEC remains a leading cause of morbidity and
mortality, identifying preterm infants at increased risk for
developing the condition remains an important but elusive
objective. Previous studies suggested an association between the
risk of NEC and the SNPs VEGF C-2578A, IL-18 C-607A (14),
and IL-4Rα A-1902G (15). In the present cohort we could not
confirm the association between theVEGF C-2578A and IL-18C-
607A SNPs and the risk of NEC or the combined outcome NEC
or death before 34 weeks of corrected gestation. However, the
co-dominant, dominant, recessive, and additive models showed
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TABLE 3 | Genotype characteristics of the VEGF C-2578A, IL-18 C-607A, and IL-4 receptor α-chain A-1902G polymorphism in total preterm study group (n = 358) and
term control group (n = 96).
Chromosomal
location
Allele W/M Total study group
WW/WM/MM alleles
(prevalence of
mutant allele)
Missing
data
(n)
HWE
(P-value)
Term control group
WW/WM/MM alleles
(prevalence of
mutant allele)
Missing data
(n)
HWE in controls
(P-value)
VEGF C-2578A 6p21.1 C/A 109/155/85 (0.466) 9 0.04* 33/47/16 (0.411) 0 0.92
IL-18 C-607A 11q23.1 C/A 102/177/78 (0.466) 1 0.94 27/48/18 (0.452) 3 0.69
IL-4 R A-1902G 16p12.1 A/G 179/134/45 (0.313) 0 0.01* 56/29/10 (0.258) 1 0.049*
Results are expressed as absolute numbers of patients. Missing data due to technical inability of genotyping sample.
HWE, Hardy–Weinberg Equilibrium; W, wild type allele; M, mutant allele.
*P < 0.05.
TABLE 4 | Genotype distribution and minor allele frequency of the VEGF C-2578A, IL-18 C-607A, and IL-4 R A-1902G polymorphisms for NEC ≥stage II, NEC stage III
and the combined outcome NEC or death before 34 weeks of corrected gestational age.
SNP Genotype NEC-no
n (%)
MAF NEC (≥stage II)-yes
n (%)
MAF NEC (stage III)-yes
n (%)
MAF NEC/death-no
n (%)
MAF NEC/death-yes
n (%)
MAF
VEGF C-2578A CC 101 (31.2) 0.468 8 (32.0) 0.440 2 (20.0) 0.500 95 (31.3) 0.467 14 (31.1) 0.456
CA 143 (44.1) 12 (48.0) 6 (60.0) 134 (44.1) 21 (46.7)
AA 80 (24.7)† 5 (20.0) 2 (20.0) 75 (24.6)† 10 (22.2)
IL-18 C-607A CC 96 (29.0) 0.465 6 (23.1) 0.481 5 (45.5) 0.318 85 (27.8) 0.474 17 (33.3) 0.422
CA 162 (48.9) 15 (57.7) 5 (45.5) 152 (49.7) 25 (49.0)
AA 73 (22.1) 5 (19.2) 1 (9.1) 69 (22.5) 9 (17.7)
IL-4 R A-1902G AA 165 (49.7) 0.318 14 (53.8) 0.250 7 (63.6) 0.227 147 (47.9) 0.331 32 (62.7) 0.206*
AG 123 (37.0) 11 (42.3) 3 (27.3) 117 (38.1) 17 (33.3)
GG 44 (13.3)†† 1 (3.9) 1 (9.1) 43 (14.0)†† 2 (4.0)
SNP, single-nucleotide polymorphism; NEC, necrotizing enterocolitis; MAF, minor allele frequency.
CC denotes homozygosity for the C-encoded VEGF C-2578A and IL-18 C-607A polymorphism variant; AA homozygosity for the A-encoded VEGF C-2578A and IL-18 C-607A
polymorphism variant; CA heterozygosity for VEGF C-2578A and IL-18 C-607A polymorphism; AA denotes homozygosity for the A-encoded IL4R A-1902G polymorphism variant; GG
homozygosity for the G-encoded IL4R A-1902G polymorphism variant; AG heterozygosity for IL4R A-1902G polymorphism.
*P < 0.05 vs. NEC/death-no.
† ,††P < 0.05, 0.01 for deviation of Hardy-Weinberg equilibrium in the disease-free group.
a significant negative association of the G-allele of the IL-4Rα A-
1902G polymorphism with the combined outcome NEC or death
before 34 weeks of corrected gestation.
This study has some limitations that need to be considered.
First, we did not investigate the functional consequences of
the SNPs. Second, the distribution of the genotypes of the
VEGF C-2578A- and the IL-4Rα A-1902G polymorphisms
in the preterm control population and the IL-4Rα A-1902G
polymorphism in the term population did not fulfill Hardy-
Weinberg criteria. Theoretically, disease-free control groups
from outbred populations should not deviate from HWE (23).
Deviation from HWE may be related to non-random mating,
population stratification, selection bias, limited sample size, or
genotyping error (23). Of note, deviation from HWE in the
control group may increase the chance of detecting a false-
positive association, particularly when ORs did not show a
strong association (23). This points to the need for caution in
interpreting our findings.
VEGF is an angiogenic protein that couples hypoxia
sensing to angiogenesis and is necessary for the development
and maintenance of capillary networks (9). It is suggested
that VEGF-mediated alterations of the intestinal mucosal
microvasculature play an important role in NEC pathogenesis
(9, 13, 24, 25). In fact, intestinal VEGF protein expression is
reduced in human and experimental NEC (9, 26). The VEGF
gene is highly polymorphic, especially in the promoter, 5′-
untranslated and 3′-untranslated regions (27). Some of these
SNPs, including the C-2578A, have been related to varying VEGF
protein expression and serum VEGFA levels and proposed to be
involved in the pathogenesis of various adult diseases (27–30).
As mentioned in the introduction, two previous studies
showed that the A allele of the VEGF C-2578A SNP increased
the risk of NEC in preterm infants (12, 13). Moreover, one of
the studies showed that plasma VEGFA levels were significantly
lower in carriers of the A allele (13). In contrast, our study could
not confirm the association between the VEGF C-2578A SNP
and NEC. Differences in the inclusion criteria and the ethnic
background of the studied populations may account for these
different results. The study of Banyasz et al. included infants
with all stages of NEC (12), whereas our study and the study
of Gao et al. (13) only included infants with confirmed NEC
(Bell stage II disease or greater). As highlighted by Cuna et al.,
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a precise phenotypic definition of NEC is essential in the design
of genetic studies and only confirmed cases of NEC in preterm
infants should be included. The study of Gao et al. (13) involved
a Chinese Han population and a simple association may not
translate to a population of different ethnic backgrounds (31). An
important point of consideration is that the Chinese population
has a lower prevalence of the A allele of the VEGF C-2578A SNP
(32–34) than the Caucasian population (28).
Excessive inflammation is a hallmark in the pathogenesis
of NEC and, therefore, many investigators have examined the
potential association between several SNPs of pro-and anti-
inflammatory cytokine genes and NEC (3, 10). Altered IL-18
levels are present in patients with inflammatory bowel disease
(35) and IL-18 deficient mice are showed decreased intestinal
damage following experimental NEC (36). Alterations of IL-18
production have been associated with the C-607A SNP of the IL-
18 gene (37). Heninger et al. showed in a case-control studies
including 136 preterm newborns (46 NEC, 90 control) that the
frequency of the AA genotype of the C-607A SNP was higher in
infants with stage III NEC compared to those with stages I–II and
those without NEC (14). We could not replicate their results in
our cohort.
IL-4 is another cytokine with powerful anti-inflammatory
actions. Th1-cell proliferation is inhibited by IL-4 and IL-
4 opposes the effects of pro-inflammatory cytokines on
macrophages. Isolated lamina propria mononuclear cells from
inflamed intestine expressed IL-4 mRNA and secreted this
cytokine in lower amounts than control cells (38, 39). The IL-
4Rα A-1902G polymorphism has been shown to affect receptor
signaling and the anti-inflammatory effect of IL-4 is more
pronounced in peripheral blood mononuclear cells from adults
carrying the G-variant of the SNP (40). Trezl et al. showed
that carriers of the mutant allele of the IL-4Rα A-1902G
polymorphism had a lower risk of all stages of NEC (15). In
contrast, our study could not demonstrate an association between
the IL-4Rα A-1902G SNP and the risk of NEC (≥ Bell stage
II). Nevertheless, we found a significant negative association
of the G-allele of the IL-4Rα A-1902G polymorphism with the
combined outcome NEC or death before 34 weeks of corrected
gestation in all genetic models. We analyzed this combined
outcome because epidemiological studies indicate that the time
to onset of NEC follows a bimodal distribution with a first peak
around at 1 week of age and a second peak around at the end
of the third week of life (41, 42). Therefore, early death is a
competing outcome for NEC.
As reported by Treszl et al. (15, 38), the IL-4Rα G1902 variant
does not influence IL-4 levels, but its presence is associated
with enhanced transduction of IL-4 signals. This enhanced IL-4
transduction is known to shift the development of lymphocytes
to a more pronounced Th2 proliferation. They speculate that
the elevated number of Th2 cells in carriers of this genetic
polymorphism is a protective factor against the development of
NEC (15, 38). Accordingly, our data suggest that the minor G
variant of the IL-4RαA-1902G SNP might protect against the
combined outcome NEC/early death. However, there is still a
need for further studies to determine the mechanisms of the
protective role of the IL-4Rα G1902 variant in NEC.
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CONCLUSION
This is one of the largest cohort studies investigating the
association of SNPs involved in the homeostasis of intestinal
microcirculation and inflammatory response with NEC. We
observed that the IL-4Rα A-1902G genotype was associated with
the risk of developing the combined outcome of NEC or death
before 34 weeks PMA. Nevertheless, NEC is a condition with
a complex and multifactorial pathogenesis and, therefore, an
isolated genetic derangement may not be sufficient to account
for the entire complexity of the disease. Many genetic variations
associated to prematurity, intestinal function, microcirculatory
regulation, inflammatory signaling, or immune defense could
protect or increase the susceptibility of preterm infants to NEC
(3, 43). The future challenge resides in identifying the haplotypes
that confer increased risk for NEC and in understanding their
interaction with environmental risk factors. In addition, further
investigation is required to determine functional consequences of
each SNP.
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